Publications

by | June 21, 2012 | Uncategorized

Counterfeit medicines: What role for patients?

The Council of Europe’s eTACT project project is a collaborative system to better, in support of the Falsified Medicines Directive, secure the legal supply-chain of medicinal products from manufacturers to consumers. It proposes a flexible structure that could provide patients with a role in the identification of falsified medicines by using new technology to check the authenticity of products. However, instead of ’empowering’ patients and enhancing trust, the effects could in fact be the opposite.

eTACT was started by the European Directorate for the Quality of Medicines and HealthCare (EDQM) in mid-2009. The project is one element of the Council of Europe’s holistic strategy to combat falsified medicinal products – it also includes activities related to customs, medicines, and inspection testing. The eTACT project envisages placing a Unique Medicine Identifier on the secondary packaging of medicinal products in the form of a barcode that can be scanned.

Although, both in Europe and globally, there are differing and uneven systems already in place at national level, the eTACT system differs to them in three ways:
– level of traceability (e.g. verification only by pharmacies vs. at multiple points along the supply line);
– governance (pharmacy-level only vs. authorities/independent third parties); and
– involvement of patients

There are thus two proposals for the eTACT system: The first one would end at pharmacy level and it recognises pharmacists’ role as trustworthy gatekeepers who can prevent fake medicines from falling into the hands of patients and educate the latter about them.

The alternative would allow for more flexibility across the supply chain, which in theory could potentially create additional layers of security as a greater number of stakeholders (e.g. wholesalers) would also play a role. In practice however, there are concerns about opening the process to other parts, like the risk of patients using smart phones or the internet to authenticate medicinal products. In this context, the eTACT project team is currently consulting relevant stakeholders to determine whether or not this idea is something worth pursuing given the general drive towards more patient involvement in EU health policy.

A roundtable held on 21 June at the Council of Europe (Brussels office) further explored these issues. The preliminary comments received from patient groups and other stakeholders including EPHA was that this could shift additional responsibility and burden on patients, especially given the widespread lack of literacy about counterfeit medicines and the harmful consequences of taking them. Moreover, in line with the EPHA position on Counterfeit Medicines, providing patients with an increased role could actually have the opposite effect of that intended, which is that patients might have less trust in the entire supply chain if they were themselves responsible for detecting falsified products. While it is not that this could work as an additional feature (if the role of the patient in the process as well as the required actions are clearly defined), the costs involved in implementing such a multi-level system may be better spent on combating the flaws of the supply chain itself, especially the commercial activities of illegal internet pharmacies that may not always be clearly recognisable as such.

Moreover, even with new identifiers placed on secondary packaging a ‘perfect copy’ of a product simply cannot be traced. It is also a reality that many patients are simply not as concerned about counterfeit products as they should be, partly due to lack of knowledge about the harm that these can potentially cause, but also because some people knowingly accept that counterfeit products are in circulation and they will take them regardless, especially when ”the price is right”. Hence there would have to be a collective effort including health professionals and patient groups to educate and sensitise people to these issues. As stated in the EPHA position, the costs implied by new safety features need to be spread across the whole supply chain to avoid a price increase of medicines, otherwise they will only lead to further health inequalities in Europe.

While EPHA welcomes the Directive’s role in decreasing the penetration of counterfeits through safety features, batch traceability and mandatory logos for certified internet pharmacies, the delegated acts will better explain how certain safety features (e.g., serialisation) will work, and the standards to be respected by the Member States since full harmonisation is not an option.

—-
For further information

– DG SANCO – Falsified Medicines
– [Council of Europe eTACT programme
->https://www.coe.int/etact-programme]

EPHA related articles
– [->5024]
– [->3919]
– [->5197]

Get the EPHA Newsletter

The best of our activities, right in your inbox!